ImmunicIMUX
IMUX
About: Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.
Employees: 85
0
Funds holding %
of 6,823 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
140% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 5
49% more capital invested
Capital invested by funds: $62.1M [Q2] → $92.4M (+$30.2M) [Q3]
21% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 14
9% more funds holding
Funds holding: 57 [Q2] → 62 (+5) [Q3]
0.16% more ownership
Funds ownership: 62.0% [Q2] → 62.16% (+0.16%) [Q3]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q2] → 1 (+0) [Q3]
83% less call options, than puts
Call options by funds: $118K | Put options by funds: $698K
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$10
953%
upside
Avg. target
$14.67
1,444%
upside
High target
$17
1,689%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
D. Boral Capital Jason Kolbert 39% 1-year accuracy 76 / 193 met price target | 1,689%upside $17 | Buy Maintained | 7 Jan 2025 |
HC Wainwright & Co. Matthew Caufield 19% 1-year accuracy 10 / 52 met price target | 953%upside $10 | Buy Initiated | 25 Nov 2024 |
EF Hutton Jason Kolbert 39% 1-year accuracy 76 / 193 met price target | 1,689%upside $17 | Buy Maintained | 7 Nov 2024 |
Financial journalist opinion
Based on 3 articles about IMUX published over the past 30 days
Positive
Proactive Investors
1 week ago
Immunic eyes transformative year ahead for MS therapy vidofludimus calcium - ICYMI
Immunic Inc (NASDAQ:IMUX) chief operating officer Jason Tardio joined Proactive to discuss the company's progress in advancing its novel therapy vidofludimus calcium. He discussed the significant milestones achieved in 2024, such as the positive interim analysis of the ENSURE trials in relapsing multiple sclerosis (MS) and the anticipation of the results from the CALLIPER progressive MS study in April 2025.
Positive
Proactive Investors
2 weeks ago
Immunic eyes key data readout from multiple sclerosis trial in 2025
Immunic Inc (NASDAQ:IMUX) has reflected on key milestones achieved in 2024, including advancing its novel therapy, vidofludimus calcium, toward key data readouts and securing significant funding to progress its clinical programs. In a statement, the company said it expects top-line data from the Phase 2 CALLIPER trial of vidofludimus calcium in progressive multiple sclerosis (PMS) in April 2025.
Neutral
PRNewsWire
2 weeks ago
Immunic Highlights 2024 Accomplishments and Upcoming Milestones
– Top-Line Data from Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis Expected in April – – Reported Positive Outcome from Interim Analysis of Ongoing, Twin Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis; Both Trials on Track to Be Completed in 2026 – – Strengthened Management Team and Board of Directors with Key Hires – – Announced a Three-Tranche Private Placement Totaling Up to $240 Million, Extending Cash Runway Into the Third Quarter of 2025, Based on Initial $80 Million Tranche – NEW YORK , Jan. 7, 2025 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today highlighted its 2024 accomplishments and upcoming milestones. "The past year was marked by substantial progress for our orally available lead asset, nuclear receptor related 1 (Nurr1) activator, vidofludimus calcium (IMU-838), as we continued to advance both our phase 2 CALLIPER trial in patients with progressive multiple sclerosis (PMS) and our twin phase 3 ENSURE trials in relapsing multiple sclerosis (RMS)," stated Daniel Vitt, Ph.D.
Neutral
PRNewsWire
1 month ago
Immunic, Inc. to Participate in Investor Conference in December
NEW YORK, Nov. 26, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that Daniel Vitt, Ph.D., Chief Executive Officer of Immunic, will participate in a fireside chat on Thursday, December 5, 2024, at 11:30 am ET, during the Piper Sandler 36th Annual Healthcare Conference, taking place December 3-5, 2024, in New York.
Positive
Proactive Investors
2 months ago
Immunic's IMU-856 shows potential in gastrointestinal health trials - ICYMI
Immunic Inc (NASDAQ:IMUX) Chief Medical Officer Dr. Andreas Muehler talked with Proactive about the publication of the company's Phase 1 and Phase 1b clinical trial results for IMU-856 in The Lancet Gastroenterology & Hepatology.
Positive
Proactive Investors
2 months ago
Immunic reports positive Phase 1 results for celiac disease therapy published in The Lancet
Immunic Inc (NASDAQ:IMUX) announced that data from its phase 1/1b clinical trial for IMU-856, a small molecule targeting SIRT6, has been published in The Lancet Gastroenterology & Hepatology. The study, led by Dr James Daveson, a gastroenterologist with Wesley Research Institute in Australia, evaluated IMU-856's safety and efficacy in patients with celiac disease.
Neutral
PRNewsWire
2 months ago
Immunic Announces Publication of Data From Phase 1/1b Clinical Trial of IMU-856 in the Peer Reviewed Journal, The Lancet Gastroenterology & Hepatology
– Includes Phase 1 Data in Healthy Human Subjects and Phase 1b Data in Celiac Disease Patients – NEW YORK , Nov. 13, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that the data from its phase 1/1b clinical trial of IMU-856, an orally available and systemically acting small molecule modulator that targets SIRT6 (Sirtuin 6), has been published in the peer reviewed journal, The Lancet Gastroenterology & Hepatology. Lead authored by Dr. A.
Neutral
Seeking Alpha
2 months ago
Immunic, Inc. (IMUX) Q3 2024 Earnings Call Transcript
Immunic, Inc. (NASDAQ:IMUX ) Q3 2024 Earnings Conference Call November 7, 2024 8:00 AM ET Company Participants Jessica Breu - Vice President Investor Relations and Communications Daniel Vitt - Chief Executive Officer and Director Glenn Whaley - Chief Financial Officer Jason Tardio - President and Chief Operating Officer Conference Call Participants William Wood - B. Riley Matt Cowper - Leerink Partners Matt Kaplan - Ladenburg Operator Good morning, and welcome to Immunic's Third Quarter 2024 Earnings Call.
Positive
Proactive Investors
2 months ago
Immunic highlights progress in multiple sclerosis programs, targets 2025 milestones
Immunic Inc (NASDAQ:IMUX) ended the third quarter with over $59 million in cash to advance its key clinical programs, including its lead candidate, vidofludimus calcium (IMU-838), for multiple sclerosis (MS). During the third quarter ended September 30, 2024, the firm advanced both its phase 2 CALLIPER trial in patients with progressive multiple sclerosis (PMS) and a twin phase 3 ENSURE trials in relapsing multiple sclerosis (RMS) looking at orally available lead asset, nuclear receptor related 1 (Nurr1) activator, IMU-838.
Neutral
PRNewsWire
2 months ago
Immunic, Inc. Reports Third Quarter 2024 Financial Results and Provides Corporate Update
– Positive Interim Analysis of Phase 3 ENSURE Program, Unblinded Independent Data Monitoring Committee Confirmed that Predetermined Futility Criteria Have Not Been Met and Recommended Trials Should Continue as Planned – – Ongoing, Twin Phase 3 ENSURE Trials in Relapsing Multiple Sclerosis and Phase 2 CALLIPER Trial in Progressive Multiple Sclerosis Remain on Track – – Top-Line Data from Phase 2 CALLIPER Trial Expected in April 2025 – – Webcast to be Held Today, November 7, at 8:00 am ET – NEW YORK , Nov. 7, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced financial results for the third quarter and nine months ended September 30, 2024, and provided a corporate update. "During the third quarter, we have continued to advance both our phase 2 CALLIPER trial in patients with progressive multiple sclerosis (PMS) and our twin phase 3 ENSURE trials in relapsing multiple sclerosis (RMS), for our potentially transformative, orally available lead asset, nuclear receptor related 1 (Nurr1) activator, vidofludimus calcium (IMU-838)," stated Daniel Vitt, Ph.D.
Charts implemented using Lightweight Charts™